Treatment with Calquence resulted in fewer toxicities, including atrial fibrillation, flutter and hypertension, in patients with previously treated chronic lymphocytic leukemia, compared with Imbruvica treatment, according to findings from the analysis of a phase 3 trial.
Cancer survivors may experience psychological side effects of cancer and can benefit from stress management interventions, although these in-person services are often limited.
A breast cancer survivor describes a project she participated in — the Dear Body Project — to thank her body for all that it has endured.
From former Boston Red Sox pitcher Jim Corsi’s death after cancer to how “Sweet Valley High” actress Brittany Daniel’s unique experience after cancer caused pregnancy difficulties, here’s what’s happening in the cancer landscape this week.
Relatlimab plus Opdivo improved progression-free survival in patients with untreated, advanced melanoma, and tended to have fewer side effects than other regimens used in this patient population.
Certain allergy medications like Zyrtec and Claritin may be the key for more patients to tolerate immunotherapy for several cancer types.
“It is frequently said that the best screening test is the one patients are willing to complete,” a researcher said. However, some experts note that colonoscopies are the gold standard for detecting and confirming colorectal cancer.
A pancreatic cancer survivor explains how he learned to live after cancer and reflects on lessons learned from the book, “Tuesdays with Morrie.”
In this episode of the “Cancer Horizons” podcast, an expert unpacks cancer risks for individuals with Down syndrome and analyzes the results of a recent study about mortality risks for childhood survivors later in life.
An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.
The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.
Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.
After a challenging year due to COVID-19 and rising blood test numbers, a woman living with ovarian cancer shares on what she’s learned and how she’s approaching 2022.
An expert from the Mayo Clinic explained that the use of a combination of drugs including Darzalex in the first-line setting may lead to better outcomes for patients with multiple myeloma instead of other first-line standard-of-care options.
The recent FDA approval of Keytruda, an immunotherapy monoclonal antibody drug, for children with melanoma is an exciting development, according to an expert. But there is potential for certain side effects that children and their family should consider before undergoing treatment.
From long-term effects of pediatric cancer to a survivor fulfilling her dream of being an astronaut, CURE® looked back on its most-read childhood cancer stories of the year.
A sister of a woman with cancer writes about how the idea of recurrence faded to the back of her mind, but now she must be realistic about the future.
The Food and Drug Administration will offer guidance and expedited review to CLN-081, a novel drug that is promising for the treatment of EGFR exon 20-mutated non-small cell lung cancer.
From an overview of the disease to notable deaths and clinicians who go the extra mile, here is a list of CURE®’s most-read myeloma articles from 2021.
The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.
Patients with Down syndrome have an increased risk for leukemia during childhood, and toxicities related to treatment may be more common in this patient population.
A cancer survivor pens a poem about his New Year’s resolutions to help other survivors through obstacles in 2022.
Patients with a common brain tumor subtype that expresses ERK1/2 activation may obtain a greater survival benefit with PD-1 immunotherapy, although research needs to confirm whether this can be observed in all patients.
An oncologist from Fox Chase Cancer Center in Philadelphia explains the early career mentorship that inspired his successful lung cancer career.
Not having known much about lung cancer, a woman describes her shock at receiving a diagnosis despite being a non-smoker.
CURE® compiled its top 5 most-listened-to podcast episodes from this year, featuring cancer survivor stories, caregivers and experts.
A lung cancer doctor explains how he got lucky to fill in a role in the lung cancer space, and his career and passion took off from there.
A woman who has worked with Upal Basu Roy in the lung cancer space for many years explains why he is a lung cancer hero to everyone he has worked with, due to his dedication and empathy.
A young adult cancer survivor describes the ways people typically misunderstand his cancer experiences.
As the standard treatment for patients with renal cell carcinoma, the most common type of kidney cancer, related to VHL disease is often surgical procedures, the use of Welireg may reduce surgical burden in patients.
